GB808269A - Barbiturate pharmaceutical preparations - Google Patents

Barbiturate pharmaceutical preparations

Info

Publication number
GB808269A
GB808269A GB3161357A GB3161357A GB808269A GB 808269 A GB808269 A GB 808269A GB 3161357 A GB3161357 A GB 3161357A GB 3161357 A GB3161357 A GB 3161357A GB 808269 A GB808269 A GB 808269A
Authority
GB
United Kingdom
Prior art keywords
glutarimide
methyl
ethyl
dimethyl
glutaric acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
GB3161357A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nicholas Ltd Pty
Original Assignee
Nicholas Ltd Pty
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to AU808269X priority Critical
Application filed by Nicholas Ltd Pty filed Critical Nicholas Ltd Pty
Publication of GB808269A publication Critical patent/GB808269A/en
Application status is Expired legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A61K31/515Barbituric acids; Derivatives thereof, e.g. sodium pentobarbital

Abstract

b : b - Methyl - ethyl - glutaramic acid is prepared by treating b : b -methyl-ethyl-glutaric anhydride in water with ammonia followed by acidification with hydrochloric acid. b : b -Methyl-ethyl-dithioglutarimide is prepared by boiling methyl-ethyl-glutarimide in xylene with phosphorus pentasulphide. b : b - Methyl - isobutyl-glutarimide is prepared by heating b : b -methyl-isobutyl-glutaric acid with urea. a : b -Dimethyl - b - ethyl - glutarimide is prepared by treating a : a 1 - dicyano - b : b - methyl - ethyl-glutarimide with dimethyl sulphate in presence of sodium and absolute alcohol to give N - methyl - a : a 1 - dicyano - a - methyl - b : b - methyl-ethyl-glutarimide, converting this by treatment with sulphuric acid to N-methyl-a : b - dimethyl - b - ethyl - dicarbamoyl - glutarimide, hydrolysing this with sulphuric acid to a : b - dimethyl - b - ethyl - glutaric acid, distilling this to give a : b -dimethyl-b -ethyl-glutaric acid anhydride and heating this with urea.ALSO:A pharmaceutical preparation comprising a medicinal barbiturate and a substituted glutaric acid derivative selected from b ,b -methyl ethyl glutaramic acid, b ,b -methyl ethyl dithioglutarimide, b -spirocyclopentane glutarimide, b -spirocyclohexane glutarimide, b -spirocycloheptane glutarimide, b ,b - dimethyl glutarimide, b ,b - diethyl glutarimide, b ,b - methyl isobutyl glutarimide, b ,b -methyl-n-propyl glutarimide, a ,b ,b - trimethyl glutarimide, a ,b - dimethyl - b - ethyl glutarimide, a - ethyl - b ,b - dimethyl glutarimide and camphoric acid imide, or mixtures thereof in an amount insufficient to interfere with a therapeutic dose of barbiturate but sufficient to overcome the toxic effects of overdose. Specified barbiturates are phenobarbitone, amylobarbitone, butobarbitone, pentobarbitone sodium, quinolbarbitone sodium, hexobarbitone sodium. The proportion of substituted glutaric acid derivative should be 5-200 per cent, preferably 25-150 per cent, by weight of the barbiturate. In addition the preparation may include b ,b -methyl ethyl glutarimide; mild stimulants such as caffeine and amphetamine; mild sedatives such as sodium bromide; hypnotics such as chloral and paraldehyde; analgesics such as aspirin, phenacetin and codeine; antiasthmatics such as ephidrine; anticholinergics such as atropine; anticonvulsants such as hydantoin. The preparation may be in the form of an injection, suppository, tablet, elixir or capsule and may embody an agent when in capsule or tablet form, delaying the release of the substituted glutaric acid derivative. In tablet form the barbiturate may form a layer compressed over a core containing substituted glutaric acid derivative.
GB3161357A 1956-10-10 1957-10-09 Barbiturate pharmaceutical preparations Expired GB808269A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU808269X 1956-10-10

Publications (1)

Publication Number Publication Date
GB808269A true GB808269A (en) 1959-01-28

Family

ID=3759794

Family Applications (1)

Application Number Title Priority Date Filing Date
GB3161357A Expired GB808269A (en) 1956-10-10 1957-10-09 Barbiturate pharmaceutical preparations

Country Status (1)

Country Link
GB (1) GB808269A (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3966940A (en) * 1973-11-09 1976-06-29 Bristol-Myers Company Analgetic compositions
US4048316A (en) * 1974-03-04 1977-09-13 Penn Nathar W Composition for antagonizing the narcotic effects of barbiturate addiction and withdrawal effects, and for treatment of barbiturate poisoning
US7682634B2 (en) 2006-06-19 2010-03-23 Alpharma Pharmaceuticals, Llc Pharmaceutical compositions
US8623418B2 (en) 2007-12-17 2014-01-07 Alpharma Pharmaceuticals Llc Pharmaceutical composition
US8685444B2 (en) 2002-09-20 2014-04-01 Alpharma Pharmaceuticals Llc Sequestering subunit and related compositions and methods

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3966940A (en) * 1973-11-09 1976-06-29 Bristol-Myers Company Analgetic compositions
US4048316A (en) * 1974-03-04 1977-09-13 Penn Nathar W Composition for antagonizing the narcotic effects of barbiturate addiction and withdrawal effects, and for treatment of barbiturate poisoning
US8685444B2 (en) 2002-09-20 2014-04-01 Alpharma Pharmaceuticals Llc Sequestering subunit and related compositions and methods
US8685443B2 (en) 2002-09-20 2014-04-01 Alpharma Pharmaceuticals Llc Sequestering subunit and related compositions and methods
US7682634B2 (en) 2006-06-19 2010-03-23 Alpharma Pharmaceuticals, Llc Pharmaceutical compositions
US7682633B2 (en) 2006-06-19 2010-03-23 Alpharma Pharmaceuticals, Llc Pharmaceutical composition
US8158156B2 (en) 2006-06-19 2012-04-17 Alpharma Pharmaceuticals, Llc Abuse-deterrent multi-layer pharmaceutical composition comprising an opioid antagonist and an opioid agonist
US8846104B2 (en) 2006-06-19 2014-09-30 Alpharma Pharmaceuticals Llc Pharmaceutical compositions for the deterrence and/or prevention of abuse
US8877247B2 (en) 2006-06-19 2014-11-04 Alpharma Pharmaceuticals Llc Abuse-deterrent multi-layer pharmaceutical composition comprising an opioid antagonist and an opioid agonist
US8623418B2 (en) 2007-12-17 2014-01-07 Alpharma Pharmaceuticals Llc Pharmaceutical composition

Similar Documents

Publication Publication Date Title
AT275402B (en) Vessel wall closure and to processes for its preparation
FR91714E (en) tris salts (para-dialkylaminophényl) aminium as absorbers of infra-red radiation and compositions containing
NL180211C (en) Process for the preparation of cosmetic compositions and process for the preparation of benzylidene camphor derivatives to be used therein.
IL59004D0 (en) Substituted benzamides their preparation and pharmaceutical compositions containing them
NL179725C (en) Process for the preparation and / or manufacture of a pharmaceutical composition for the treatment of hyperlipidemia in warm-blooded animals on the basis of a benzoic acid derivative; process for the preparation of a benzoic acid derivative to be used thereby.
MY8600471A (en) Powdery pharmaceutical composition and powdery preparation for application to the nasal mucosa and method for administration thereof
DE2705051A1 (en) Pharmaceutical preparations to prevent the misuse of addictive agents
PT84359A (en) Process for the preparation of granules containing an active substance and to the use thereof as speckles for treating substrates
IT954469B (en) Improvement in bicondilari joints to human limbs ficial arts
IL58849D0 (en) Amino acid derivatives their preparation and pharmaceutical compositions containing them
SE7514589A (en) Amino acid preparations for patients with liver disease and seen that anvenda these preparations
DE2960292D1 (en) 17-beta-thiocarboxylic acid esters of 4-halo-3-oxoandrost-4-enes, their pharmaceutical use and processes for their preparation
DK70579A (en) Clothing to provide thermal insulation and protection of a building as well as the process for its preparation
ES2029269T5 (en) A slow-release formulation.
DK0429039T3 (en) Use of an opiate antagonist for the preparation of a pharmaceutical composition to be administered transdermally, as well as means for transdermal delivery
ZA7802897B (en) Controlled-release compositions for administration of therapeutic agents to ruminants
JPS5345400A (en) Preparation of polyoxazolidone compound
JPS60136512A (en) Remedy and preventive for hyperlipemia
KR0145739B1 (en) Effervescent tablet
ES2159382T3 (en) stilbene compounds adamantyl, compositions containing and uses.
SG285G (en) Benzimidazoles,their preparation and pharmaceutical compositions containing them
DK490178A (en) Process for the preparation of a pharmaceutical composition in unit dosage form for use kapselpaefyldningsmaskine d veat the procedure as well as the manufactured pharmaceutical praepar
IE48300B1 (en) Improvements in or relating to post fracture stability of limbs
IL59917D0 (en) Monoclonal antibody to human t cells,its preparation and pharmaceutical compositions containing it
JPS6431729A (en) Novel use for 5ht-3 antagonist